Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors
2017-01-01 Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials
2011-01-01 Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crinò, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, E on bealf of GOIRC and NVALT groups
Renal metastases to pancreas: do not operate all and always?
2014-01-01 Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S
The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study
2017-01-01 Vitale, Mg; Masini, C; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report
2014-01-01 Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study
2007-01-01 Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
2015-01-01 Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G
Maintenance biotherapy for metastatic renal cancer with IL-2 and IFN-alpha: A Phase III, randomized, multicentre trial
2004-01-01 Passalacqua, R; Buzio, C; Labianca, R; Porta, C; Dalla Chiesa, M; Buti, S; Tomasello, G; Camisa, R; Frassoldati, A; Caminiti, C
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab
2017-01-01 Tiseo, M; Veneziani, M; Gelsomino, F; Facchinetti, F; Bordi, P; Rapacchi, E; Squadrilli, A; Buti, S; Missale, G; Ardizzoni, A
Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients
2012-01-01 Bordi, P; Buti, S; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, S; Pilotto, S; Camisa, R; Ardizzoni, A
Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
2007-01-01 Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R
Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD)
2013-01-01 Masini, C; Porta, C; Milella, M; Procopio, G; Di, Lorenzo G; Santoni, M; Buti, S; Iacovelli, R; Invernizzi, R; Moscetti, L; Aste, Mg; Pagano, M; Grosso, F; Manenti, Al; Ortega, C; Cosmai, L; Nicodemo, M; Donati, D; Del Giovane, C; Sabbatini, R
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents
2017-01-01 Grassi, P; Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Ratta, R; Procopio, G
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers
2009-01-01 Brighenti, M; Passalacqua, R; Naldi, N; Buti, S; Lazzarelli, S; Potenzoni, D; Potenzoni, M; Benecchi, L; Fumagalli, M; Losardo, ; Monica, B; Caminiti, C
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial
2012-01-01 Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib)
2008-01-01 Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report
2014-01-01 Bracarda, S; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Harnzaj, A; Altavilla, A; De Angelis, V
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial
2007-01-01 Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R
LOH as "the missing instability" potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer
2016-01-01 Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
2017-01-01 De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in mRCC patients treated with immune-checkpoint inhibitors | 1-gen-2017 | Bersanelli, M; Gnetti, L; Vaglio, A; Sverzellati, N; Campanini, N; Galetti, M; Incerti, M; Varotti, E; Parziale, R; Corrado, M; Bottarelli, L; Azzoni, C; Rapacchi, E; Caruso, G; Cosenza, A; Ferri, L; Silini, Em; Leonardi, F; Buti, S | |
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials | 1-gen-2011 | Tiseo, M; Ardizzoni, A; Boni, L; Vincent, A; Buti, S; Camerini, A; Labianca, R; Genestreti, G; Zanelli, F; Ciuffreda, L; Di Costanzo, F; De Marinis, F; Crinò, L; Santo, A; Pazzola, A; Barbieri, F; Zilembo, N; Colantonio, I; Tibaldi, C; Smit, E on bealf of GOIRC and NVALT groups | |
Renal metastases to pancreas: do not operate all and always? | 1-gen-2014 | Burattini, L; Santoni, M; Porta, C; Sternberg, Cn; Procopio, G; Basso, U; De Giorgi, U; Rizzo, M; Ortega, C; Massari, F; Masini, C; Milella, M; Di Lorenzo, G; Cerbone, L; Conti, A; Buti, S; Partelli, S; Falconi, M; Santini, D; Cascinu, S | |
The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study | 1-gen-2017 | Vitale, Mg; Masini, C; Procopio, G; De Giorgi, U; Buti, S; Rossetti, S; Iacovelli, R; Mucciarini, C; Cosmai, L; Vignani, F; Prati, G; Scagliarini, S; Berselli, A; Pinto, C | |
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report | 1-gen-2014 | Altavilla, A; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Hamzaj, A; Marrocolo, F; De Angelis, V; Bracarda, S | |
Dose-dense chemotherapy (CT) with modified TCF regimen (TCF-DD) in metastatic gastric cancer (MGC): A Phase II study | 1-gen-2007 | Dalla Chiesa, M; Tomasello, G; Buti, S; Negri, F; Buononato, M; Longarini, R; Porzio, R; Lazzarelli, S; Brighenti, M; Passalacqua, R | |
Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs) | 1-gen-2015 | Santini, D; Santoni, M; Conti, A; Procopio, G; Verzoni, E; Galli, L; di Lorenzo, G; De Giorgi, U; De Lisi, D; Nicodemo, M; Maruzzo, M; Massari, F; Buti, S; Biasco, E; Ricotta, R; Porta, C; Vincenzi, B; Marchetti, P; Cascinu, S; Tonini, G | |
Maintenance biotherapy for metastatic renal cancer with IL-2 and IFN-alpha: A Phase III, randomized, multicentre trial | 1-gen-2004 | Passalacqua, R; Buzio, C; Labianca, R; Porta, C; Dalla Chiesa, M; Buti, S; Tomasello, G; Camisa, R; Frassoldati, A; Caminiti, C | |
Circulating immune-profile as predictor of outcome in NSCLC patients treated with nivolumab | 1-gen-2017 | Tiseo, M; Veneziani, M; Gelsomino, F; Facchinetti, F; Bordi, P; Rapacchi, E; Squadrilli, A; Buti, S; Missale, G; Ardizzoni, A | |
Erythrocyte mean corpuscolar volume change during pemetrexed chemotherapy in advanced non small cell lung cancer patients | 1-gen-2012 | Bordi, P; Buti, S; Tiseo, M; Panni, S; Novello, S; Bria, E; Rapetti, S; Pilotto, S; Camisa, R; Ardizzoni, A | |
Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial | 1-gen-2007 | Buti, S; Lazzarelli, S; Simonelli, C; Venturini, S; Spazzapan, S; Lo Re, G; Mattioli, R; Dalla Chiesa, M; Brighenti, M; Passalacqua, R | |
Safety of targeted therapies (TTs) in metastatic renal cell carcinoma (mRCC) patients in haemodialysis (HD) | 1-gen-2013 | Masini, C; Porta, C; Milella, M; Procopio, G; Di, Lorenzo G; Santoni, M; Buti, S; Iacovelli, R; Invernizzi, R; Moscetti, L; Aste, Mg; Pagano, M; Grosso, F; Manenti, Al; Ortega, C; Cosmai, L; Nicodemo, M; Donati, D; Del Giovane, C; Sabbatini, R | |
TARIBO trial: Cytoreductive nephrectomy in metastatic renal cell carcinoma patients treated with targeted agents | 1-gen-2017 | Grassi, P; Verzoni, E; Bearz, A; Bracarda, S; Bregni, M; Buti, S; Cinieri, S; De Giorgi, U; Fornarini, G; Galli, L; Milella, M; Morelli, F; Nole, F; Passalacqua, R; Sabbatini, R; Santini, D; Salvioni, R; Cappelletti, V; Ratta, R; Procopio, G | |
Long-term results and health-related quality of life (QoL) after a bladder preservation program using chemotherapy plus radiotherapy in muscle invasive bladder cancer (BC). Effects of p53 and others predictive markers | 1-gen-2009 | Brighenti, M; Passalacqua, R; Naldi, N; Buti, S; Lazzarelli, S; Potenzoni, D; Potenzoni, M; Benecchi, L; Fumagalli, M; Losardo, ; Monica, B; Caminiti, C | |
Factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) with or without estramustine (E) as first-line treatment for castration-resistant prostate cancer (CRPC): Preliminary results of HOPLITE trial | 1-gen-2012 | Caffo, O; Lo Re, G; Sava, T; Buti, S; Sacco, C; Basso, U; Zustovich, F; Martini, T; Perin, A; Veccia, A; Russo, L; Facchini, G; Barile, C; Gernone, A; Pappagallo, Gl; Galligioni, E | |
Correlazione TC-PET nel follow-up di GIST metastatici trattati con terapia antitirosinchinasica (Imatinib) | 1-gen-2008 | Mazza, G; Archiati, E; Voltini, G; Olivetti, L; Buti, S; Passalacqua, R | |
Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWN): A preliminary report | 1-gen-2014 | Bracarda, S; Procopio, G; Alesini, D; Grillone, F; Massari, F; Zaniboni, A; Mattioli, R; Buti, S; Garanzini, E; Sisani, M; Harnzaj, A; Altavilla, A; De Angelis, V | |
Bevacizumab (B) plus immunotherapy and chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC). Dose-finding/phase II trial | 1-gen-2007 | Buti, S; Brighenti, M; Dalla Chiesa, M; Simonelli, C; Passalacqua, R | |
LOH as "the missing instability" potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer | 1-gen-2016 | Bersanelli, M; Gnetti, L; Azzoni, C; Bottarelli, L; Gasparro, D; Leonardi, F; Silini, Em; Buti, S | |
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP) | 1-gen-2017 | De Giorgi, U; Procopio, G; Guida, A; Bearz, A; Buti, S; Basso, U; Mitterer, M; Ortega, C; Bidoli, P; Ferrau, F; Crino, L; Frassoldati, A; Marchetti, P; Mini, E; Scoppola, A; Verusio, C; Fornarini, G; Carteni, G; Caserta, C; Sternberg, Cn |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Articolo su rivista1657
Data di pubblicazione
- 2020 - 2024117
- 2010 - 2019802
- 2000 - 2009512
- 1990 - 1999174
- 1980 - 198951
- 1979 - 19791
Editore
- ASCO pubs11
- ELSEVIER9
- Elsevier7
- SAGE PUBLICATIONS LTD5
- Edra3
- INT UNION CRYSTALLOGRAPHY3
- LIPPINCOTT WILLIAMS & WILKINS3
- SPRINGERNATURE3
- WILEY3
- BioMed Central2
Rivista
- DIGESTIVE AND LIVER DISEASE101
- GASTROENTEROLOGY100
- BLOOD89
- ANNALS OF ONCOLOGY78
- HAEMATOLOGICA56
- JOURNAL OF CLINICAL ONCOLOGY51
- NEUROLOGICAL SCIENCES46
- UNITED EUROPEAN GASTROENTEROLOGY ...46
- ANNALS OF THE RHEUMATIC DISEASES30
- REUMATISMO26
Keyword
- Helicobacter pylori10
- sclerosi sistemica6
- Bioengineering5
- Gastroenterology5
- HCV5
- UV5
- GERD4
- anodal stimulation3
- beat-to-beat variability of cardi...3
- capillaroscopia3
Lingua
- eng848
- ita160
- fre1
Accesso al fulltext
- no fulltext1625
- reserved26
- open6